{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Specimen+Collection&page=22", "query": { "intervention": "Specimen Collection", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 1155, "total_pages": 116, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Specimen+Collection&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Specimen+Collection&page=21&page_size=10" }, "source": "local", "last_synced_at": "2026-10-15T20:35:33.894Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07619521", "title": "Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Pancreatic Ductal Adenocarcinoma", "Metastatic Pancreatic Ductal Adenocarcinoma", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Diagnostic Imaging Testing", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2027-06-01", "completion_date": "2028-09-08", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-15T20:35:33.894Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07619521" }, { "nct_id": "NCT07025538", "title": "Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biomarker Analysis", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "PROCEDURE", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2026-04-29", "completion_date": "2028-06-22", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-03T00:02:06.117Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07025538" }, { "nct_id": "NCT06453044", "title": "Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3a Follicular Lymphoma", "Refractory Grade 1 Follicular Lymphoma", "Refractory Grade 2 Follicular Lymphoma", "Refractory Grade 3a Follicular Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mosunetuzumab", "type": "BIOLOGICAL" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2024-09-09", "completion_date": "2028-03-14", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-15T20:13:56.333Z", "location_count": 2, "location_summary": "Duarte, California • Irvine, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06453044" }, { "nct_id": "NCT05172245", "title": "Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Head and Neck Carcinoma of Unknown Primary", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Locally Advanced Hypopharyngeal Squamous Cell Carcinoma", "Locally Advanced Laryngeal Squamous Cell Carcinoma", "Locally Advanced Nasal Cavity Squamous Cell Carcinoma", "Locally Advanced Oral Cavity Squamous Cell Carcinoma", "Locally Advanced Oropharyngeal Squamous Cell Carcinoma", "Locally Advanced Paranasal Sinus Squamous Cell Carcinoma", "Locally Advanced Sinonasal Squamous Cell Carcinoma", "Maxillary Sinus Squamous Cell Carcinoma", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage III Sinonasal Cancer AJCC v8", "Stage IVA Hypopharyngeal Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Sinonasal Cancer AJCC v8", "Stage IVB Hypopharyngeal Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Lip and Oral Cavity Cancer AJCC v8", "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVB Sinonasal Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2022-09-19", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-14T09:34:08.323Z", "location_count": 17, "location_summary": "Tampa, Florida • Chicago, Illinois • Fairway, Kansas + 13 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05172245" }, { "nct_id": "NCT00001595", "title": "An Investigation of Pituitary Tumors and Related Hypothalmic Disorders", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cushing Disease", "Gigantism/Acromegaly", "Panhypopituitarism", "Prolactinoma" ], "interventions": [ { "name": "MRI", "type": "PROCEDURE" }, { "name": "Tissue specimen collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "2 Years to 70 Years" }, "enrollment_count": 2000, "start_date": "1997-04-21", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-14T09:19:34.585Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001595" }, { "nct_id": "NCT07645651", "title": "Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Borderline Resectable Pancreatic Ductal Adenocarcinoma", "Locally Advanced Pancreatic Ductal Adenocarcinoma", "Resectable Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Endoscopic Ultrasound Biopsy", "type": "PROCEDURE" }, { "name": "Samuraciclib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2026-10-15", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-08T00:24:38.102Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07645651" }, { "nct_id": "NCT07495124", "title": "IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Carcinoma", "Ovarian Carcinoma", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 26, "start_date": "2026-09-16", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-14T11:43:50.434Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07495124" }, { "nct_id": "NCT06821997", "title": "NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Borderline Resectable Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Sucrosofate", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-03-02", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-14T11:25:47.602Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06821997" }, { "nct_id": "NCT06439836", "title": "Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Urothelial Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Emavusertib", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-05-05", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-01T12:04:41.478Z", "location_count": 11, "location_summary": "Duarte, California • Irvine, California • La Jolla, California + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06439836" }, { "nct_id": "NCT06160791", "title": "Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hemophagocytic Lymphohistiocytoses" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Non-interventional Imaging", "type": "PROCEDURE" }, { "name": "Research Biopsy", "type": "PROCEDURE" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Jerry Lee, MD, MSc, MPhil", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2024-10-01", "completion_date": "2029-11-30", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-12T00:11:12.244Z", "location_count": 4, "location_summary": "Irvine, California • Sacramento, California • San Diego, California + 1 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06160791" } ] }